Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HRMY stock price vs BNTX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BNTX's multiple
Needs BNTX P/E.
Implied fair value · at HRMY's multiple
Needs Annual EPS is negative, HRMY P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
USD conversion input: 1 EUR = 1.161400 USD. FX date unavailable.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BioNTech SE · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
Moderna, Inc.
HRMY vs MRNA
GILEAD SCIENCES, INC.
HRMY vs GILD
AMGEN INC
HRMY vs AMGN
REGENERON PHARMACEUTICALS, INC.
HRMY vs REGN
INCYTE CORP
HRMY vs INCY
VERTEX PHARMACEUTICALS INC / MA
HRMY vs VRTX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HRMY can sustain its 21.5% revenue growth and 24.0% operating margin while the market rerates it closer to even a modestly higher sales multiple, then HRMY looks attractive because it is profitable and much cheaper than BNTX on P/S and EV/Revenue.
HRMY trades at 2.4x P/S versus BNTX at 6.8x, yet HRMY is profitable while BNTX is loss-making. On the provided framework, the current price of $35.31 sits well below BNTX-implied $101.77 and also below the $31.78-$38.84 historical band midpoint, suggesting the market is discounting HRMY despite superior fundamentals.
Supporting Metrics
